Bell Bank Increases Stake in Pfizer Inc. $PFE

Bell Bank grew its stake in Pfizer Inc. (NYSE:PFE) by 18.4% in the 2nd quarter, according to its most recent filing with the SEC. The firm owned 433,983 shares of the biopharmaceutical company’s stock after buying an additional 67,441 shares during the quarter. Pfizer accounts for approximately 0.5% of Bell Bank’s portfolio, making the stock its 26th biggest position. Bell Bank’s holdings in Pfizer were worth $10,520,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Gould Capital LLC boosted its stake in shares of Pfizer by 97.2% in the 4th quarter. Gould Capital LLC now owns 1,000 shares of the biopharmaceutical company’s stock valued at $27,000 after buying an additional 493 shares during the period. GKV Capital Management Co. Inc. purchased a new position in shares of Pfizer in the 1st quarter valued at about $27,000. Bayforest Capital Ltd purchased a new stake in Pfizer during the first quarter worth approximately $28,000. North Capital Inc. purchased a new stake in Pfizer during the first quarter worth approximately $28,000. Finally, Bernard Wealth Management Corp. purchased a new stake in Pfizer during the fourth quarter worth approximately $30,000. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Analyst Upgrades and Downgrades

PFE has been the subject of several recent analyst reports. Berenberg Bank decreased their target price on Pfizer from $28.00 to $25.00 and set a “hold” rating for the company in a research note on Thursday, May 29th. Wall Street Zen upgraded Pfizer from a “hold” rating to a “buy” rating in a research note on Saturday. Bank of America boosted their target price on Pfizer from $27.00 to $28.00 and gave the stock a “neutral” rating in a research note on Wednesday, August 6th. Citigroup boosted their target price on Pfizer from $25.00 to $26.00 and gave the stock a “neutral” rating in a research note on Wednesday, August 6th. Finally, Morgan Stanley boosted their target price on Pfizer from $32.00 to $33.00 and gave the stock an “equal weight” rating in a research note on Wednesday, August 6th. Two research analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, eleven have issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Pfizer presently has an average rating of “Hold” and an average price target of $28.12.

Pfizer Price Performance

Shares of NYSE PFE opened at $24.03 on Friday. The company has a current ratio of 1.16, a quick ratio of 0.85 and a debt-to-equity ratio of 0.65. Pfizer Inc. has a twelve month low of $20.92 and a twelve month high of $30.43. The stock has a 50 day moving average of $24.63 and a two-hundred day moving average of $24.22. The stock has a market cap of $136.62 billion, a P/E ratio of 12.78, a P/E/G ratio of 0.85 and a beta of 0.55.

Pfizer (NYSE:PFE) last issued its quarterly earnings data on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share for the quarter, beating analysts’ consensus estimates of $0.58 by $0.20. The company had revenue of $14.65 billion during the quarter, compared to analysts’ expectations of $13.43 billion. Pfizer had a return on equity of 21.42% and a net margin of 16.84%.The firm’s revenue for the quarter was up 10.3% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.60 earnings per share. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. On average, research analysts forecast that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Tuesday, September 2nd. Stockholders of record on Friday, July 25th were issued a $0.43 dividend. The ex-dividend date of this dividend was Friday, July 25th. This represents a $1.72 dividend on an annualized basis and a dividend yield of 7.2%. Pfizer’s payout ratio is presently 91.49%.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.